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Dear Editor, 
Vitiligo is a chronic disorder causing skin depigmentation with around 1% global 
prevalence, affecting people of all ages, skin types and genders.1 Due to the absence of 
melanin in lesional skin there is a theoretical concern that there might be a higher risk of 
skin cancer in people with vitiligo. However, some studies have shown that the genetic 
and autoimmune profiles of vitiligo patients may confer a degree of protection against 
the development of melanoma and non-melanoma skin cancer (NMSC).2 Therefore, the 
aim of this systematic review was to quantify the risk of skin cancer (melanoma and 
NMSC) in people with vitiligo compared to those without vitiligo. 
We registered the review protocol with PROSPERO on July 19th 2017 (CRD42017072493) 
and reported our study following MOOSE guidelines. We searched three databases 
(PubMed, Embase and Web of Science), from inception to July 12th 2017, for 
observational studies meeting the inclusion criteria (see the protocol for further details). 
We also searched the British Association of Dermatologists clinical guideline for vitiligo 
and UK E-Theses depository for any relevant studies. Two authors (LB and SL) 
independently performed title/abstract and full text screening, quality assessment (using 
Joanna Briggs Institute’s (JBI) critical appraisal tool) and data extraction. Disagreements 
were resolved by discussion with another author (SR). Random effects meta-analysis 
was used to combine the results. 
A total of 2,177 studies were identified, of which 12 full text articles were assessed for 
eligibility. Of these, five studies were eligible to be included in the review. We searched 
the references of the five studies and also their Google Scholar citations, and identified 
one extra study. Of the six studies included in the review, four were included in the 
meta-analysis. Details of the search strategy and the PRISMA flow diagram are available 
on request to the corresponding author. 
All but one study were hospital-based.3-8 Four studies were cross-sectional,3-6 of which 
three compared people with vitiligo to people without vitiligo and one compared vitiligo 
skin to non-vitiligo skin on the same group of patients (Table 1).6 The remaining two 
studies were cohort7 and case-control8 studies. The number of people with vitiligo in the 
included studies ranged from 19 to 10,040. Only one study was deemed to be of high 
quality,8 scoring 7 out of 10 using the JBI tool. The main reason for poor quality was lack 
of comparability between people with and without vitiligo. One study adjusted for 
phototherapy.4 The meta-analyses for NMSC and melanoma combined results from three  
studies each3-5,8 which included a total of 11,447 and 11,366 people with vitiligo, 
respectively The two studies excluded from the meta-analysis found no events of skin 
cancer in either vitiligo nor non-vitiligo groups (366 patients excluded).6,7 Compared to 
people without vitiligo, people with vitiligo had a significantly lower risk of NMSC; the 
crude odds ratio was 0.29 (95% confidence intervals (95%CI) 0.14-0.58, I-squared 
75.9%). The same pattern occurred for melanoma but the crude odds ratio was not 
statistically significant; 0.52 (95%CI 0.15-1.78, I-squared 85.3%). Forest plots available 
on request to the corresponding author. 
This review supports the current view that vitiligo may be protective of skin cancer. This 
could be due to the genetic and autoimmune profile of vitiligo, or the fact that patients 
with vitiligo are more careful regarding sun protection than those without vitiligo. This is 
the first review in this clinical area which has searched the literature comprehensively 
and synthesised data in a systematic way. However, our review is limited by the small 
number of included studies and high heterogeneity due to methodological and clinical 
differences between the included studies. Furthermore, the lack of studies has prohibited 
subgroup analysis and assessment of publication bias. 
The main methodological limitation of the included studies was lack of adequate 
comparison with the controls. Furthermore, most of the studies either had an 
inappropriate study design or were hospital-based, limiting the internal and external 
validity of the results. Finally, it is important to acknowledge studies that assessed the 
association between melanoma and vitiligo may have biased results because vitiligo 
occurring during melanoma or treatment of melanoma is very difficult to differentiate 
from vitiligo itself. Future research implications include the need for a population-based 
longitudinal study with appropriate comparisons.. Once more appropriate research has 
been conducted in this field, clinicians may be able to reassure people with vitiligo that 
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